Pomerantz LLP is investigating AstraZeneca and its executives for potential securities fraud following the failure of the Phase-3 CARDIO-TTransform trial for Wainua, a heart disease drug. The trial did not meet its primary endpoint, causing AstraZeneca's stock to drop 5.7% on July 9, 2026. The investigation aims to determine if AstraZeneca engaged in unlawful business practices. Investors affected by the stock decline are encouraged to contact the law firm for potential class action participation.
The FTSE 100 index gained 40 points to 10,777, supported by a drop in oil prices following a pause in US-Iran strikes and easing retail sector downturn. Retail sales improved in July, though online sales fell sharply, and wholesale volumes stabilized...
AstraZeneca reported second-quarter earnings that surpassed analyst expectations, with core earnings per share rising 21% to $2.63, though revenue slightly missed forecasts at $15.4 billion. Growth in oncology and rare diseases offset weaker sales fr...
Jefferies maintains a buy rating on AstraZeneca, highlighting that detailed data on its lung drug tozorakimab, due on 8 September, could offset the impact of a failed heart trial. The lung drug targets IL-33, potentially benefiting a broader COPD pat...
Jefferies maintains a buy rating on AstraZeneca, expecting detailed data on its lung drug tozorakimab in September to compensate for a recent heart trial failure. The failed CARDIO-TTRansform study cut $4 billion from forecasts, but Jefferies believe...
